Of the 17 confirmed episodes of pericarditis, 14 (82.4%) occurred before establishment on prophylactic immunomodulatory therapy, 2 while on low‐dose colchicine, and 1 while on the anti‐IL‐1β monoclonal antibody canakinumab. This evidence concerns the gene IL1B and pericarditis.